Approval of Audited Financial Statements for the Financial Year 2024 - 25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shanmuga Hospital's board approved audited FY25 results showing revenue from operations of Rs. 48.05 crores, up about 11% from Rs. 43.04 crores in FY24. However, profit after tax fell roughly 20% to Rs. 4.21 crores (from Rs. 5.25 crores) and profit before tax fell to Rs. 5.69 crores from Rs. 7.02 crores, as total expenses grew faster (~17%) than revenue. Cash flow from operations turned sharply negative at Rs. -12.64 crores versus Rs. +9.58 crores last year. The company recently listed on BSE SME in February 2025 via an IPO that raised Rs. 20.6 crores, boosting cash and bank balances to Rs. 12.6 crores and reserves to Rs. 26.1 crores. The board also gave in-principle approval for a new Nephro Care Unit, approved closure of the Salem pharmacy unit effective May 31, 2025, and re-appointed internal and secretarial auditors. The statutory auditor (PPN and Company) issued an unmodified (clean) opinion on the results.
Mixed picture for shareholders – healthy revenue growth and a stronger balance sheet post-IPO, but weaker profitability and a swing to negative operating cash flow may weigh on sentiment, while the planned Nephro Care unit offers a future growth lever.